# Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

> **NCT00323791** · PHASE2 · TERMINATED · sponsor: **University of Medicine and Dentistry of New Jersey** · enrollment: 100 (estimated)

## Conditions studied

- Kidney Cancer

## Interventions

- **DRUG:** gemcitabine hydrochloride
- **DRUG:** imatinib mesylate
- **GENETIC:** gene expression analysis
- **GENETIC:** protein expression analysis
- **OTHER:** immunohistochemistry staining method
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00323791
- **Lead sponsor:** University of Medicine and Dentistry of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-04
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 100 (ESTIMATED)
- **Why stopped:** slow accrual
- **Last updated:** 2009-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00323791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00323791, "Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT00323791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*